title: The genetics of a pharma merger.
abstract: The 1990s and early years of this century have seen a series of large-scale mergers and acquisitions in the Pharmaceutical and Biotech arena. These activities each required integration at multiple levels. One of the most important activities is the integration of the R&D pipelines of the participants. We outline the combined portfolio and bioinformatic strategy that was used, and detail the lessons learned for the longer term, from the GlaxoWellcome-SmithKline-Beecham merger in 2000. To date, this has been the largest merger of two equally sized Pharma R&D organisations.
authors.affiliation: Molecular Discovery Research, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom.
authors.forename: Philippe
authors.initials: P
authors.lastname: Sanseau
authors.forename: Marie
authors.initials: M
authors.lastname: Chabot-Fletcher
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Browne
mesh_terms: D003132:Commerce / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D017598:Efficiency, Organizational / Q000191:economics; D015894:Genome, Human; D006801:Humans; D007449:Investments / Q000191:economics / Q000458:organization & administration*; D008967:Molecular Biology; D009936:Organizational Innovation / Q000191:economics; D010597:Pharmacogenetics; D012106:Research